Tidemark LLC Purchases Shares of 9,054 Alphatec Holdings, Inc. (NASDAQ:ATEC)

Tidemark LLC acquired a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,054 shares of the medical technology company’s stock, valued at approximately $137,000.

Several other hedge funds also recently modified their holdings of the stock. RiverPark Advisors LLC bought a new position in shares of Alphatec in the 3rd quarter valued at about $53,000. Provence Wealth Management Group acquired a new position in Alphatec during the third quarter worth approximately $56,000. Van ECK Associates Corp bought a new stake in Alphatec in the third quarter valued at approximately $113,000. Amalgamated Bank boosted its stake in shares of Alphatec by 7.3% during the 4th quarter. Amalgamated Bank now owns 9,720 shares of the medical technology company’s stock worth $147,000 after acquiring an additional 660 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Alphatec by 23.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,120 shares of the medical technology company’s stock worth $157,000 after acquiring an additional 2,331 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Alphatec Stock Performance

Shares of NASDAQ:ATEC traded down $0.37 during midday trading on Thursday, hitting $10.39. The stock had a trading volume of 239,680 shares, compared to its average volume of 1,670,901. The company has a debt-to-equity ratio of 13.63, a current ratio of 2.39 and a quick ratio of 1.49. The company’s 50-day moving average price is $12.83 and its 200-day moving average price is $13.60. Alphatec Holdings, Inc. has a fifty-two week low of $8.66 and a fifty-two week high of $19.14.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Tuesday, May 7th. The medical technology company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The business had revenue of $138.48 million for the quarter, compared to analyst estimates of $134.07 million. Alphatec had a negative return on equity of 1,767.81% and a negative net margin of 37.45%. Alphatec’s quarterly revenue was up 26.9% on a year-over-year basis. During the same period last year, the firm posted ($0.40) EPS. Research analysts predict that Alphatec Holdings, Inc. will post -1.05 EPS for the current year.

Insider Transactions at Alphatec

In other news, COO Scott Lish sold 31,075 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $15.19, for a total value of $472,029.25. Following the sale, the chief operating officer now directly owns 507,165 shares in the company, valued at approximately $7,703,836.35. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Alphatec news, CFO John Todd Koning sold 37,500 shares of the stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $12.82, for a total value of $480,750.00. Following the completion of the transaction, the chief financial officer now directly owns 393,356 shares in the company, valued at $5,042,823.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Scott Lish sold 31,075 shares of Alphatec stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $15.19, for a total value of $472,029.25. Following the sale, the chief operating officer now directly owns 507,165 shares in the company, valued at $7,703,836.35. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 252,786 shares of company stock valued at $3,474,224. 22.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

ATEC has been the subject of a number of research analyst reports. Piper Sandler reduced their price objective on shares of Alphatec from $19.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, May 8th. Wells Fargo & Company assumed coverage on Alphatec in a research report on Friday, February 9th. They issued an “overweight” rating and a $26.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Monday, March 4th. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price objective on shares of Alphatec in a research report on Wednesday, May 8th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $25.00 price target on shares of Alphatec in a research note on Wednesday, March 20th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $22.89.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.